表紙
市場調查報告書
商品編碼
747134

糖尿病治療藥的全球市場的預測:各疾病、各類型 (口服治療藥,注射藥,胰島素)、各地區、各企業

Diabetes Drug Market Global & Forecast By Disease, Oral Therapy, Injection, Insulin, Regions, Company

出版日期: | 出版商: Renub Research | 英文 276 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球糖尿病治療藥的市場規模,預計到2026年末達781億美元。市場主要原因為,高齡化人口的增加和新藥銷售量的擴大,第二型糖尿病的盛行率的上升,技術進步等。各地區中,美國佔最大的佔有率。

該報告,全球糖尿病治療藥的市場相關分析,市場整體結構和趨勢預測 (以金額、數量為準,過去4年、今後7年份),疾病的各類型 (1型/2型)、各治療藥物、各地區的詳細趨勢,主要企業的簡介,主要的促進、阻礙因素等資訊彙整,為您概述為以下內容。

第1章 簡介

第2章 研究和分析方法

第3章 摘要整理

第4章 全球糖尿病治療藥的市場

第5章 市場佔有率:全球糖尿病治療藥市場

  • 疾病的各類型
  • 各治療藥物(口服藥,注射藥,胰島素)
  • 各地區:第一型糖尿病治療藥
  • 各地區:第二型糖尿病治療藥

第6章 全球糖尿病治療藥市場:疾病的各治療 疾病類型-全世界的糖尿病的藥的市場

  • 第一型糖尿病藥市場
  • 第二型糖尿病藥市場

第7章 全球糖尿病治療藥市場:治療藥的各類型

  • 口服藥
    • (DPP) IV抑制劑
    • SGLT-2
    • Alpha Glucosidase抑制劑
    • 雙胍
    • 其他口服藥
  • 注射劑
    • 類升糖素肽(GLP)1促效劑
    • Amylin受體刺激藥
  • 胰島素
    • 速效性胰島素
    • 持續性胰島素
    • 雙相胰島素 (預混合胰島素)
    • 其他

第8章 全球第一型糖尿病市場:各地區 各地區整體類型1糖尿病的藥物的市場

  • 南北美洲
  • 5歐洲聯盟
  • 日本
  • 加拿大

第9章 全球第二型糖尿病市場:各地區

  • 南北美洲
  • 5歐洲聯盟
  • 日本
  • 中國
  • 印度
  • 巴西

第10章 全球第一型/第二型糖尿病的患者數:各地區

  • 美國的糖尿病患者人口
    • 第一型糖尿病的患者數
    • 第二型糖尿病的患者數
  • (EU5)的糖尿病患者人口歐洲主要5個國家
  • 日本的糖尿病患者人口
  • 加拿大的糖尿病患者人口
  • 中國的糖尿病患者人口
  • 印度的糖尿病患者人口
  • 巴西的糖尿病患者人口

第11章 合併和收購

第12章 市場動態

  • 成長促進因素
    • 糖尿病的盛行率上升
    • 糖尿病治療費的增加
  • 課題
    • 糖尿病酮酸症
    • 重度的低血糖
    • 體重增加
  • 市場機會

第13章 主要企業分析

  • Novo Nordisk
    • 概要
    • 研究開發 (R&D) 管道
    • 銷售量分析
  • 默克
  • Merck & Co
  • Eli Lilly
  • AstraZeneca
  • Johnson & Johnson
  • Boehringer Ingelheim
  • 其他
目錄

Diabetes drugs are medications that have been prescribed to treat specific diabetes forms such as Type 1 and Type 2 diabetes. Diabetes medicines are used to treat diabetes mellitus to stabilize blood glucose levels through various drugs such as Insulin, Metformin, and Sulphonylureas. The global diabetes drug market is continuously growing at a rapid pace due to the growing prevalence of diabetes all over the world. The major key drivers of the diabetes drug market are; a growing aging population, increasing sales of novel drugs, rising prevalence of type 2 diabetes and technological advancements, etc. According to Renub Research Global Diabetes Drug Market is anticipated to reach US$ 78.10 Billion by the end of the year 2026.

The other market growth factor for diabetes drugs are; approvals of various new drugs such as Canagliflozin, Dapagliflozin, etc., for the treatment of diabetes, which would build several opportunities for the new upcoming as well as existing players in the global diabetes drugs market. The growing adoption rate of diabetes drugs in developing regions such as Asia Pacific like India, China, and Japan and Europe, Spain, France, the UK, and Germany are the important key factors, which would be driving the growth of global diabetes drugs market in upcoming years. According to our research, patient compliance is also one of the important factors in the future growth of diabetes drugs, devices, and monitoring systems used to treat diabetes.

Around the world, various governments' initiatives to control diabetes disease in a developed and developing nation will further propel the diabetes drug market. Moreover, the high manufacturing cost of drugs, low awareness among people about diabetes treatment and insulin devices are projected to create restrictive to the growth of the diabetes drugs market.

Small and well-established players have as future collaboration, expansion, acquisition, partnership, and new product launch to increase competitive benefits in this market and to uphold the market position in the future. The manufacturers are continually improving their strategy to analyze and update the new product and launching a new solution to meet the changing needs of both patients and health care professionals, which accelerate the global diabetes drug market.

Some of the drugs used to treat type 2 diabetes are Metformin, Actos, Avandia, Lantus subcutaneous, and Invokana. All drugs are administered orally except insulin, Exenatide, Liraglutide, and Pramlintide. Insulin is delivered through insulin delivery devices including infusion pump, intravenous sets, insulin syringe, insulin pen, and jet injectors. Long-acting, intermediate-acting, short-acting, and rapid-acting are some of the types of insulin used to treat diabetes.

Renub Research report titled "Diabetes Drug Market Global & Forecast By Disease (Type 1, Type 2), Oral Therapy ((DPP) IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide, and Others Oral Drug), Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin receptor against), Insulin (Rapid - Acting Insulin, Long Acting Insulin, Premixed Insulin, and Other Insulin), Regions (United States, Canada, 5European Union, Japan, China, India, and Brazil), Company (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson)" provides the complete analysis of global diabetes drugs market.

By Disease Type - Type2 Disease holds the Significant Share in the Global Diabetes Drug Market

In this report, we provide full studies of type 1 & type 2 diabetes drugs market. A type 2 diabetes drug holds significant market in the global diabetes drugs market and is anticipated to dominate the market over projection years.

By Therapy - Insulin Therapy dominates the Overall Therapy Market

In this report, we have done complete insight on global diabetes drug market and we have categorized it into three segments and sub-segments on the basis of therapy.

  • Oral

(DPP) IV inhibitor

SGLT-2

Alpha Glucosidase Inhibitor

Biguanide

Others Oral Drug

  • Injection

Glucagon-like peptide (GLP) 1 agonist

Amylin receptor against

  • Insulin

Rapid - Acting Insulin

Long Acting Insulin

Premixed Insulin

Other Insulin

By Region Type1 Diabetes - United States holds the Significant Market Shares in the Global Diabetes Drug Market

In this report, we provide complete analysis of market share for four major regions such as the United States, 5European Union, Japan and Canada. The United States holds the significant market shares in the global diabetes drugs market.

By Region Type2 Diabetes - United States Dominates Type2 Diabetes Market in Overall Global Diabetes Drugs Market

In this report, we have done complete analysis of type2 diabetes drugs by region; United States, 5European Union, Japan and Canada, China, India, and Brazil. The United States is dominates type2 diabetes market in the global diabetes drug market.

All the companies have been studied from two points

  • Recent Developments
  • Sales Analysis

Company Analysis

  • Novo Nordisk
  • Merck & Co
  • Eli Lilly
  • AstraZeneca
  • Johnson & Johnson

By Disease Type - Global Diabetes Drug Market

  • Type1 Diabetes
  • Type2 Diabetes

By Region - Global Type 1 & Type 2 Diabetes Drug Market, Population

  • United States
  • 5 European Union
  • Japan
  • China
  • India
  • Brazil

Table of Contents

1. Introductions

2. Research & Methodology

3. Executive Summary

4. Global Diabetes Drug Market

5. Market Share - Global Diabetes Drug

  • 5.1 By Disease Type
  • 5.2 By Therapy - (Oral, Injection, Insulin)
  • 5.3 By Oral Drug
  • 5.4 By Injection Drug
  • 5.5 By Insulin
  • 5.6 By Regions - Type 1 Diabetes Drug
  • 5.7 By Regions - Type 2 Diabetes Drug

6. Disease Type - Global Diabetes Drug Market

  • 6.1 Type 1 Diabetes Drug Market
  • 6.2 Type 2 Diabetes Drug Market

7. Global Diabetes Drug Market by Therapy

  • 7.1 Oral
    • 7.1.1 (DPP) IV inhibitor
    • 7.1.2 SGLT-2
    • 7.1.3 Alpha Glucosidase Inhibitor
    • 7.1.4 Biguanide
    • 7.1.5 Others Oral Drug
  • 7.2 Injection
    • 7.2.1 Glucagon-like peptide (GLP) 1 agonist
    • 7.2.2 Amylin receptor against
  • 7.3 Insulin
    • 7.3.1 Rapid - Acting Insulin
    • 7.3.2 Long Acting Insulin
    • 7.3.3 Premixed Insulin
    • 7.3.4 Other Insulin

8. Global Type 1 Diabetes Drug Market by Region

  • 8.1 United States
  • 8.2 5 European Union
  • 8.3 Japan
  • 8.4 Canada

9. Global Type 2 Diabetes Drug Market by Region

  • 9.1 United States
  • 9.2 5 European Union
  • 9.3 Japan
  • 9.4 China
  • 9.5 India
  • 9.6 Brazil

10. Global Type1 & Type 2 Diabetes Population Market by Region

  • 10.1 United States Diabetes Population
    • 10.1.1 Type1 Diabetes Population
    • 10.1.2 Type 2 Diabetes Population
  • 10.2 5European Union Diabetes Population
    • 10.2.1 Type1 Diabetes Population
    • 10.2.2 Type 2 Diabetes Population
  • 10.3 Japan Diabetes Population
    • 10.3.1 Type1 Diabetes Population
    • 10.3.2 Type 2 Diabetes Population
  • 10.4 Canada Diabetes Population
    • 10.4.1 Type1 Diabetes Population
    • 10.4.2 Type 2 Diabetes Population
  • 10.5 China Diabetes Population
    • 10.5.1 Type1 Diabetes Population
    • 10.5.2 Type 2 Diabetes Population
  • 10.6 India Diabetes Population
    • 10.6.1 Type1 Diabetes Population
    • 10.6.2 Type 2 Diabetes Population
  • 10.7 Brazil Diabetes Population
    • 10.7.1 Type1 Diabetes Population
    • 10.7.2 Type 2 Diabetes Population

11. Merger & acquisitions

12. Market Dynamics

  • 12.1 Growth Driver
    • 12.1.1 The rising prevalence of Diabetes
    • 12.1.2 The Rising Cost of Diabetes Care
  • 12.2 Challenges
    • 12.2.1 Diabetic Ketoacidosis
    • 12.2.2 Severe Hypoglycemia
    • 12.2.3 Weight Gain
  • 12.3 Opportunities

13. Key Players Analysis

  • 13.1 Novo Nordisk
    • 13.1.1 Overview
    • 13.1.2 R&D Pipeline
    • 13.1.3 Sales Analysis
  • 13.2 Merck & Co
    • 13.2.1 Overview
    • 13.2.2 R&D Pipeline
    • 13.2.3 Sales Analysis
  • 13.3 Eli Lilly
    • 13.3.1 Overview
    • 13.3.2 R&D Pipeline
    • 13.3.3 Sales Analysis
  • 13.4 AstraZeneca
    • 13.4.1 Overview
    • 13.4.2 R&D Pipeline
    • 13.4.3 Sales Analysis
  • 13.5 Johnson & Johnson
    • 13.5.1 Overview
    • 13.5.2 R&D Pipeline
    • 13.5.3 Sales Analysis
  • 13.6 Boehringer Ingelheim
    • 13.6.1 Overview
    • 13.6.2 R&D Pipeline
    • 13.6.3 Sales Analysis
  • 13.7 Others

List of Figures:

Figure-01: Global - Diabetes Drugs Market size (Million US$), 2020 & 2026

Figure-02: Global - Diabetes Drugs Growing Segments

Figure-03: Global - Diabetes Drugs Market (Million US$), 2016 - 2019

Figure-04: Global - Forecast for Diabetes Drugs Market(Million US$), 2020 - 2026

Figure-05: Global - Diabetes Drugs Market Share by Disease type (Percent), 2016 - 2019

Figure-06: Global - Forecast for Diabetes Drugs Market Share by disease type(Percent), 2020 - 2026

Figure-07: Global - Diabetes Drugs Market Share by Therapy (Percent), 2016 - 2019

Figure-08: Global - Forecast for Diabetes Drugs Market Share by Therapy (Percent), 2020 - 2026

Figure-09: Global - Diabetes Drugs Market Share by Insulin (Percent), 2016 - 2019

Figure-10: Global - Forecast for Diabetes Drugs Market Share by Insulin (Percent), 2020 - 2026

Figure-11: Global - Type1 Diabetes Drug Market Share by Regions (Percent), 2016 - 2019

Figure-12: Global - Forecast for Type1 Diabetes Drug Market Share by Regions (Percent), 2020 - 2026

Figure-13: Global - Type1 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-14: Global - Forecast for Type1 Diabetes Drugs Market (Million US$), 2020 - 2026

Figure-15: Global - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-16: Global - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-17: Global - Oral (DPP) IV Inhibitor Drug Market (Million US$), 2016 - 2019

Figure-18: Global - Forecast for Oral (DPP) IV Inhibitor Drug Market (Million US$), 2020 - 2026

Figure-19: Global - Oral SGLT-2 Drug Market (Million US$), 2016 - 2019

Figure-20: Global - Forecast for Oral SGLT-2 Drug Market (Million US$), 2020 - 2026

Figure-21: Global - Oral Alpha Glucosidase Inhibitor Drug Market (Million US$), 2016 - 2019

Figure-22: Global - Forecast for Oral Alpha Glucosidase Inhibitor Drug Market (Million US$), 2020 - 2026

Figure-23: Global - Oral Biguanide Drug Market (Million US$), 2016 - 2019

Figure-24: Global - Forecast for Oral Biguanide Drug Market (Million US$), 2020 - 2026

Figure-25: Global - Oral Others Drug Market (Million US$), 2016 - 2019

Figure-26: Global - Forecast for Oral Others Drug Market (Million US$), 2020 - 2026

Figure-27: Global - Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 Agonist Market (Million US$), 2016 - 2019

Figure-28: Global - Forecast for Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2020 - 2026

Figure-29: Global - Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2016 - 2019

Figure-30: Global - Forecast for Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2020 - 2026

Figure-31: Global - Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2016 - 2019

Figure-32: Global - Forecast for Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2020 - 2026

Figure-33: Global - Diabetes Insulin Drug Long Acting Market (Million US$), 2016 - 2019

Figure-34: Global - Forecast for Diabetes Insulin Drug Long Acting Market (Million US$), 2020 - 2026

Figure-35: Global - Diabetes Insulin Drug Premixed Market (Million US$), 2016 - 2019

Figure-36: Global - Forecast for Diabetes Insulin Drug Premixed Market (Million US$), 2020 - 2026

Figure-37: Global - Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2016 - 2019

Figure-38: Global - Forecast for Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2020 - 2026

Figure-39: United States - Type1 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-40: United States - Forecast for Type1 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-41: 5 European Union - Type 1 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-42: 5 European Union - Forecast for type 1 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-43: Japan - Type1 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-44: Japan - Forecast for Type1 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-45: Canada - Type 1 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-46: Canada - Forecast for Type1 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-47: United States - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-48: United States - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-49: 5 European Union - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-50: 5 European Union - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-51: Japan - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-52: Japan - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-53: China - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-54: China - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-55: India - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-56: India - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-57: Brazil - Type2 Diabetes Drug Market (Million US$), 2016 - 2019

Figure-58: Brazil - Forecast for Type2 Diabetes Drug Market (Million US$), 2020 - 2026

Figure-59: United States - Diabetes Population (Thousands), 2015 - 2019

Figure-60: United States - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-61: United States - Type1 Diabetes Population (Thousands), 2015 - 2019

Figure-62: United States - Forecast for Type1 Diabetes Population (Thousands), 2020 - 2026

Figure-63: United States - Type2 Diabetes Population (Thousands), 2015 - 2019

Figure-64: United States - Forecast for Type2 Diabetes Population (Thousands), 2020 - 2026

Figure-65: 5European Union - Diabetes Population (Thousands), 2015 - 2019

Figure-66: 5European Union - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-67: 5 European Union - Type1 Diabetes Population (Thousands), 2015 - 2019

Figure-68: 5 European Union - Forecast for Type1 Diabetes Population (Thousands), 2020 - 2026

Figure-69: 5European Union - Type2 Diabetes Population (Thousands), 2015 - 2019

Figure-70: 5European Union - Forecast for Type2 Diabetes Population (Thousands), 2020 - 2026

Figure-71: Japan - Diabetes Population (Thousands), 2015 - 2019

Figure-72: Japan - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-73: Japan - Type1 Diabetes Population (Thousands), 2015 - 2019

Figure-74: Japan - Forecast for Type1 Diabetes Population (Thousands), 2020 - 2026

Figure-75: Japan - Type2 Diabetes Population (Thousands), 2015 - 2019

Figure-76: Japan - Forecast for Type2 Diabetes Population (Thousands), 2020 - 2026

Figure-77: Canada - Diabetes Population (Thousands), 2015 - 2019

Figure-78: Canada - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-79: Canada - Type1 Diabetes Population (Thousands), 2015 - 2019

Figure-80: Canada - Forecast for Type1 Diabetes Population (Thousands), 2020 - 2026

Figure-81: Canada - Type2 Diabetes Population (Thousands), 2015 - 2019

Figure-82: Canada - Forecast for Type2 Diabetes Population (Thousands), 2020 - 2026

Figure-83: China - Diabetes Population (Thousands), 2015 - 2019

Figure-84: China - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-85: China - Type1 Diabetes Population (Thousands), 2015 - 2019

Figure-86: China - Forecast for Type1 Diabetes Population (Thousands), 2020 - 2026

Figure-87: China - Type2 Diabetes Population (Thousands), 2015 - 2019

Figure-88: China - Forecast for type2 Diabetes Population (Thousands), 2020 - 2026

Figure-89: India - Diabetes Population (Thousands), 2015 - 2019

Figure-90: India - Forecast for type2 Diabetes Population (Thousands), 2020 - 2026

Figure-91: India - Type1 Diabetes Population (Thousands), 2015 - 2019

Figure-92: India - Forecast for Type1 Diabetes Population (Thousands), 2020 - 2026

Figure-93: India - Type2 Diabetes Population (Thousands), 2015 - 2019

Figure-94: India - Forecast for Type2 Diabetes Population (Thousands), 2020 - 2026

Figure-95: Brazil - Diabetes Population (Thousands), 2015 - 2019

Figure-96: Brazil - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-97: Brazil - Diabetes Population (Thousands), 2015 - 2019

Figure-98: Brazil - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-99: Brazil - Diabetes Population (Thousands), 2015 - 2019

Figure-100: Brazil - Forecast for Diabetes Population (Thousands), 2020 - 2026

Figure-101: Global - Novo Nordisk Diabetes Drug Sales (Million US$), 2016 - 2019

Figure-102: Global - Forecast for Novo Nordisk Diabetes Drug Sales (Million US$), 2020 - 2026

Figure-103: Global - Merck & Co Diabetes Drug Sales (Million US$), 2016 - 2019

Figure-104: Global - Forecast for Merck & Co Diabetes Drug Sales (Million US$), 2020 - 2026

Figure-105: Global - Eli Lilly Diabetes Drug Sales (Million US$), 2016 - 2019

Figure-106: Global - Forecast for Eli Lilly Diabetes Drug Sales (Million US$), 2020 - 2026

Figure-108: Global - AstraZeneca Diabetes Drug Sales (Million US$), 2016 - 2019

Figure-109: Global - Forecast for AstraZeneca Diabetes Drug Sales (Million US$), 2020 - 2026

Figure-110: Global - Johnson & Johnson Diabetes Drug Sales (Million US$), 2015 - 2018

Figure-111: Global - Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2015 - 2019

Figure-112: Global - Forecast for Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2020 - 2026

List of Table:

Table-1: Global - Diabetes Drugs Market Share by Oral Drug (Percent), 2016 - 2019

Table-2: Global - Forecast for Diabetes Drugs Market Share by Oral Drug (Percent), 2020 - 2026

Table-3: Global - Diabetes Drugs Market Share by Injectable Drug (Percent), 2016 - 2019

Table-4: Global - Forecast for Diabetes Drugs Market Share by Injectable Drug (Percent), 2020 - 2026

Table-5: Global - Type2 Diabetes Drug Market Share by Regions (Percent), 2016 - 2019

Table-6: Global - Forecast for Type2 Diabetes Drug Market Share by Regions (Percent), 2020 - 2026

Table-7: Number of people with diabetes worldwide and per region in 2017 and 2045 (20-79 years)

Table-8: Top Therapeutic Classes By Invoice Spending